Emmes Publications | Emmes

Search

Show only items where

Author

Type

Term

Year

Keyword

Found 27 results

Author Title [ Type

] Year

Filters: Author is Dally, L [Clear All Filters]

Journal Article

Spentzou, A., Bergin, P., Gill, D., Cheeseman, H., Ashraf, A., Kaltsidis, H., et al.. (2010). Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of Human Immunodeficiency Virus-1 Vaccine Candidates. J Infect Dis, 201, 720-729. presented at the 03/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20132004

Peters, B. S., Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., et al.. (2007). Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity. Vaccine, 25, 2120-2127. presented at the 03/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17250931

Van Damme, L., Niruthisard, S., Atisook, R., Boer, K., Dally, L., Laga, M., et al.. (1998). Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS, 12(4), 433-7. presented at the 1998 Mar 05. doi:10.1097/00002030-199804000-00013

Van Damme, L., Niruthisard, S., Atisook, R., Boer, K., Dally, L., Laga, M., et al.. (1998). Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS, 12, 433-7. presented at the 1998.

Jaoko, W., Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., et al.. (2010). Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE, 5, e12873. presented at the 09/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20877623

W, J., FN, N., O, A., G, O. Manyonyi, J, B., A, N., et al.. (2008). Safety and Immunogenicity of Recombinant Low-Dosage HIV-1 A Vaccine Candidates Vectored by Plasmid pTHr DNA or Modified Vaccinia Virus Ankara (MVA) in Humans in East Africa. Vaccine, 26, 2788-2795. presented at the 03/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18440674

Fontanet, A. L., Saba, J., Chandelying, V., Sakondhavat, C., Bhiraleus, P., Rugpao, S., et al.. (1998). Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS, 12, 1851-9. presented at the 1998.

Fontanet, A. L., Saba, J., Chandelying, V., Sakondhavat, C., Bhiraleus, P., Rugpao, S., et al.. (1998). Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS, 12(14), 1851-9. presented at the 1998 Oct 01. doi:10.1097/00002030-199814000-00017

Guimarães-Walker, A., Mackie, N., McMichael, A., Weber, J., McCormack, S., Cebere, I., et al.. (2004). Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection. presented at the 2004.

Omosa-Manyonyi, G., Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., et al.. (2015). A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS One, 10, e0125954. presented at the 05/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25961283

Vasan, S., Schlesinger, S., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., et al.. (2010). Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine. PLoS ONE, 5, e8617. presented at the 01/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20111582

Menghini, F., Dally, L., Fazzini, P. F., Menotti, A., Prati, P. L., Rovelli, F., et al.. (1995). Normal behaviour of circulatory parameters during exercise. Reference values for heart rate and systemic blood pressure. The ECCIS Project data. Epidemiologia e Clinica della Cardiopatia Ischemica Silente. G Ital Cardiol, 25(8), 967-75. presented at the 1995 Aug.

Guimarães-Walker, A., Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., et al.. (2008). Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine, 26(51), 6671-7. presented at the 2008 Dec 02. doi:10.1016/j.vaccine.2008.09.016

Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., et al.. (2006). Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA-and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes. J Virol, 80, 4717-4728. presented at the 05/2006. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16641265

Merli, M., Riggio, O., & Dally, L.. (1996). Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology, 23(5), 1041-6. presented at the 1996 May. doi:10.1002/hep.510230516

Vigano, A., Dally, L., Bricalli, D., Sala, N., Pirillo, M., Saresella, M., et al.. (1999). Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatric, 135, 675-82. presented at the 1999.

Vigano, A., Dally, L., Bricalli, D., Sala, N., Pirillo, M., Saresella, M., et al.. (1999). Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr, 135(6), 675-82. presented at the 1999 Dec. doi:10.1016/s0022-3476(99)70084-3

Mariotto, A., Dally, L., Micheli, A., Canario, F., & Verdecchia, A.. (1999). Cancer prevalence in Italian regions with local cancer registries. Tumori, 85, 400-7. presented at the 1999.

Stevens, W., Kamali, A., Karita, E., Anzala, O., Sanders, E. J., Jaoko, W., et al.. (2008). Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials. PLoS ONE, 3, e2043. presented at the 04/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18446196

Kim, J., Dally, L., Ederer, F., Gaasterland, D., Van Veldhuisen, P., Blackwell, B., et al.. (2004). The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing Progression of Glaucoma from Visual Field Fluctuations. Ophthalmology, 111, 2109-2116. presented at the 11/2004. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15522379

Conference Paper

Jaoko, W., Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., et al.. (2007). Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults. In AIDS Vaccine 2007 Conference. presented at the 20/08/2007, Seattle, WA. Retrieved from http://www.vaccineenterprise.org/conference_archive/2007/index.html

Vardas, E., Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., et al.. (2005). Safety and Immunogenicity of MVA.HIVA by 3 Different Routes. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.

Peters, B., Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., et al.. (2005). Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.

Vardas, E., Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., et al.. (2007). A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine. In AIDS Vaccine 2007 Conference. presented at the 20/08/2007, Seattle, WA. Retrieved from http://www.vaccineenterprise.org/conference_archive/2007/index.html

Kamali, A., Karita, E., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, O., et al.. (2008). A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials. In AIDS Vaccine 2008 Conference. presented at the 13/10/2008, Cape Town, South Africa. Retrieved from http://www.vaccineenterprise.org/conference_archive/2008/index.html

1
2
next
last